High-flow Nasal Oxygenation in Obese Patients During Colonoscopy: a Randomized Controlled Trial (COCOON) (COCOON)

November 12, 2026 updated by: Assistance Publique - Hôpitaux de Paris

High-flow Nasal Oxygenation in Obese Patient During Colonoscopy: a Randomized Controlled Trial: the COCOON Trial

The goal of this clinical trial is to determine whether high-flow oxygen therapy (HFOT) is more effective than conventional oxygen therapy (COT) in reducing episodes of intraoperative oxygen desaturation (oxygen saturation [SpO2] ≤ 90%) during colonoscopy under general anesthesia in adults with a body mass index (BMI) of 30 kg/m² or higher.

The main question it aims to answer is:

Does high-flow oxygen therapy reduce the occurrence of intraoperative oxygen desaturation compared with conventional oxygen therapy during colonoscopy under general anesthesia? Researchers will compare high-flow oxygen therapy with conventional oxygen therapy to determine whether high-flow oxygen therapy reduces the occurrence of intraoperative oxygen desaturation.

Participants will:

Be screened during their anesthesia consultation between 60 days and 48 hours before the scheduled colonoscopy.

Be randomly assigned (1:1) to receive either conventional oxygen therapy or high-flow oxygen therapy. Receive standard monitoring and 3 minutes of pre-oxygenation according to their assigned treatment group.

Undergo colonoscopy under general anesthesia while breathing spontaneously. Be monitored for oxygen desaturation during the procedure. Have ventilatory and hemodynamic data recorded during the procedure and collected immediately after the colonoscopy.

The study will include adults scheduled for a colonoscopy at Bichat-Claude Bernard Hospital, Beaujon Hospital, or Louis Mourier Hospital.

Study Overview

Detailed Description

Prospective, multicentre, controlled, randomized, parallel-group superiority trial with a 1:1 allocation ratio, with participants blinded to the oxygen treatment received, comparing high-flow oxygen therapy (HFOT) with conventional oxygen therapy (COT) delivered through an oxygen mask. The study aims to determine whether HFOT is more effective than COT in preventing intraoperative oxygen desaturation during colonoscopy under general anesthesia in participants with a body mass index (BMI) of 30 kg/m² or higher.

Adults with a body mass index (BMI) of 30 kg/m² or higher who are scheduled to undergo a colonoscopy at Bichat-Claude Bernard Hospital, Beaujon Hospital, or Louis Mourier Hospital.

After written informed consent has been obtained, participants will be randomized by the study investigators to one of the two treatment groups: conventional oxygen therapy (COT); high-flow oxygen therapy (HFOT).

A computer-generated randomization list with a 1:1 allocation ratio and variable block sizes will be prepared by a statistician from the URC Paris Nord Secteur Ouest, in accordance with the sponsor's procedures. Allocation will be concealed, as the randomization list will not be accessible to the study team. The list will be directly integrated into CleanWEB™, a secure, centralized, 24- hour Internet platform, which will also be used for the electronic case report form (eCRF).

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Clichy, France, 92110
        • Hôpital Beaujon, département d'anesthésie-réanimation, 100 boulevard du Général Leclerc
        • Contact:
          • Stéphanie SIGAUT, Principal Investigator
      • Colombes, France, 92700
        • Hôpital Louis Mourier, département d'anesthésie-réanimation, 178 rue des Renouillers
      • Paris, France, 75018
        • Hôpital Bichat-Claude Bernard, département d'anesthésie-réanimation, 46 rue Henri Huchard
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 18 years or older.
  • Body mass index (BMI) of 30 kg/m² or higher.
  • Scheduled to undergo a colonoscopy under general anesthesia with spontaneous breathing at Bichat-Claude Bernard Hospital, Beaujon Hospital, or Louis Mourier Hospital.
  • Affiliated with a social security scheme.
  • Free, informed and written consent signed.

Exclusion Criteria:

  • Colonoscopy in a participant at high risk of aspiration requiring orotracheal intubation, defined by at least one of the following:

    • Symptomatic or severe gastroesophageal reflux disease, notably with frequent regurgitation (≥ 2 episodes per week), mainly occurring in the supine position;
    • Hiatal hernia;
    • History of bariatric surgery (sleeve gastrectomy, gastric bypass);
    • Neurodegenerative disease requiring airway protection during colonoscopy.
  • Emergency colonoscopy.

  • Chronic respiratory failure.

  • Severe heart failure.

  • Allergy to propofol.

  • Pregnant or breastfeeding woman.

  • Adult under legal protection (guardianship or curatorship).

  • Beneficiary of State Medical Aid (Aide Médicale de l'État, AME).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Conventional oxygen therapy

Participants assigned to the conventional oxygen therapy group will receive 100% oxygen at 6 L/min through an oxygen capnography mask during the 3-minute pre-oxygenation period and throughout the procedure. After pre-oxygenation, propofol will be administered by target-controlled intravenous infusion, with an initial target concentration of 2 µg/mL. The anesthetist may adjust the target concentration to achieve deep sedation according to American Society of Anesthesiologists (ASA) criteria. The colonoscopy will be performed while participants breathe spontaneously.

100% oxygen delivered at a flow rate of 6 L/min through an oxygen capnography mask, during the 3-minute pre-oxygenation period and throughout the colonoscopy performed under general anesthesia (propofol target-controlled infusion) with spontaneous breathing.

Other Names:
  • COT
  • Standard oxygen therapy
Experimental: High-flow oxygen therapy

Participants assigned to the high-flow oxygen therapy group will receive 100% oxygen at 50 L/min through an Optiflow® system (Fisher & Paykel Healthcare) during the 3-minute pre-oxygenation period and throughout the procedure. After pre-oxygenation, propofol will be administered by target-controlled intravenous infusion, with an initial target concentration of 2 µg/mL. The anesthetist may adjust the target concentration to achieve deep sedation according to American Society of Anesthesiologists (ASA) criteria. The colonoscopy will be performed while participants breathe spontaneously.

100% oxygen delivered at a flow rate of 50 L/min through an Optiflow® high-flow nasal system (Fisher & Paykel Healthcare), during the 3-minute pre-oxygenation period and throughout the colonoscopy performed under general anesthesia (propofol target-controlled infusion) with spontaneous breathing.

Other Names:
  • HFOT
  • HFNO
  • High-flow nasal cannula oxygen

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants with at least one episode of oxygen desaturation (SpO2 ≤ 90%) during the procedure
Time Frame: From the start to the end of the procedure (Day 0)

Oxygen desaturation is defined as a peripheral oxygen saturation (SpO2) ≤ 90%, regardless of its duration, measured by continuous pulse oximetry during the colonoscopy performed under general anesthesia.

From the start to the end of the procedure (Day 0)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total number of episodes of oxygen desaturation (SpO₂ ≤ 90%) during the procedure
Time Frame: From the start to the end of the procedure (Day 0)

Number of desaturation episodes (SpO2 ≤ 90%) per participant, determined from continuously recorded pulse oximetry data.

From the start to the end of the procedure (Day 0)
Cumulative duration of oxygen desaturation episodes (SpO2 ≤ 90%) relative to the total duration of the procedure
Time Frame: From the start to the end of the procedure (Day 0)

Total time (in seconds) spent with SpO2 ≤ 90%, divided by the total duration of the procedure, i.e. the fraction of procedure time spent in desaturation (between 0 and 1), determined from continuously recorded pulse oximetry data.

From the start to the end of the procedure (Day 0)
Occurrence of an episode of hypotension, defined as systolic blood pressure (SBP) < 100 mmHg, during the procedure
Time Frame: From the start to the end of the procedure (Day 0)

Determined from continuously recorded non-invasive blood pressure data.

From the start to the end of the procedure (Day 0)
Occurrence of an episode of severe bradycardia, defined as heart rate < 40 beats/minute, during the procedure
Time Frame: From the start to the end of the procedure (Day 0)

Determined from continuously recorded heart rate data.

From the start to the end of the procedure (Day 0)
Use of orotracheal intubation during the procedure
Time Frame: From the start to the end of the procedure (Day 0)

Collected from the medical record and reported in the eCRF.

From the start to the end of the procedure (Day 0)
Occurrence of a cardiac arrest during the procedure
Time Frame: From the start to the end of the procedure (Day 0)

Cardiorespiratory arrest, collected from the medical record and reported in the eCRF

From the start to the end of the procedure (Day 0)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

July 1, 2028

Study Completion (Estimated)

August 1, 2028

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe